Efficacy of diterpene ginkgolide meglumine injection in convalescent cerebral infarction and hemorheology

Abstract

Purpose: To investigate the effect of diterpene ginkgolide meglumine injection (DGMI) compared to betahistine in convalescent cerebral infarction (CI). Methods: 80 convalescent patients with CI from March 2021 and March 2022 were randomly grouped into control and study groups  comprising 40 participants each. Control and study groups received 20 mg betahistine and 25 mg DGMI respectively in 250 mL normal  saline for 1 week. The efficacy, National Institute of Health Stroke Scale (NIHSS) score, hemorheology, and adverse effects were  investigated in control and study groups Results: Total effective rate was significantly higher in study group compared to control group (p < 0.05). Also, the National Institute of  Health Stroke Scale (NIHSS) score, plasma viscosity (PV), whole blood reduced viscosity, fibrinogen (FIB), erythrocyte aggregation index  (EAI), and incidence of adverse effect were significantly lower in study group compared to control group (p < 0.05). Conclusion:  Administration of DGMI to patients in the recovery period of CI improves neurological deficit, and average blood flow velocity in the brain,  and reduces the incidence of adverse effects. Further studies with larger sample sizes and multi-center approaches will be  required to validate these findings.